Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab, Carboplatin and Radiotherapy for Head and Neck Cancer
NCT00704639Phase 2Completed
- Sponsor
- Trans-Tasman Radiation Oncology Group
- Start
- Apr 2008
- Primary completion
- Dec 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of KL-140 in head and neck squamous cell carcinoma (HNSCC), sponsored by Trans-Tasman Radiation Oncology Group. Primary endpoint: Safety and Feasibility. Started Apr 2008; status: completed.
02
Drugs
KL-140
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00704639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00704639.